US FDA took an important step to advance policies for laboratory-developed tests services and next-generation sequencing with a Nov. 15 de novo classification of a tumor-profiling system.
The de novo in question was granted – with a class II, 510(k) risk designation – to MSK-IMPACT, a next-generation sequencing (NGS) system, developed as a clinical-grade test at Manhattan-based Memorial Sloan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?